Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC
NCT04467723Phase 2Recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- May 2022
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirfenidone in non-small cell lung cancer (NSCLC), sponsored by University of Kansas Medical Center. Started May 2022; status: recruiting.
02
Drugs
pirfenidone
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04467723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04467723.